Main Library
A recent JAMA Health Forum study found that the Centers for Medicare & Medicaid Services’ End-Stage Renal Disease Treatment Choices (ETC) alternative payment model showed no statistically significant impact on the use of home dialysis or kidney transplant rates. Healthcare Innovation recently discussed the study with Amit Kapoor, M.D., chief nephrologist at Strive Health, a value-based care company focused on kidney disease.
Healthcare Innovation: Before we start talking about CMS’ ETC model and this study, could you describe your background and role at Strive?
Kapoor: I am a board-certified, practicing nephrologist. I started out in private practice in 2006, in a small group based in Darby, Pa. I was responsible for merging our practice with a larger group in the area, so we became a large nephrology group and my role evolved in the practice to take on more of a management role and I got my M.B.A. Then I started working closely with DaVita on their value-based care model. This opportunity came along with Strive in 2021 to lead provider relationships. We’ve expanded our footprint to over 700 nephrologists throughout the country, working with us on CKCC [Comprehensive Kidney Care Contracting] and other value-based contracts. I oversee that from a clinical lens. As the chief nephrology officer, I work on the provider integration, provider engagement, customer success, really supporting our practices to drive best outcomes.